secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001601485-25-000099
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio Therapeutics announces IDMC positive recommendation to continue Phase 2 pancreatic cancer trial to final analysis
--------------------------------------------------------------------------------

- IDMC recommended AMPLIFY-7P trial continue to final analysis without modifications based on pre-specified interim review of safety and efficacy.
- Final disease-free survival analysis anticipated in Q4 2025; company remains blinded to trial outcomes.
- Cash runway extends into Q1 2026, past the expected final DFS readout.
- Elicio previously reached FDA alignment on key elements of planned pivotal Phase 3 study design.
- ELI-002 7P is an off-the-shelf immunotherapy targeting seven KRAS mutations in pancreatic ductal adenocarcinoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148525000099/0001601485-25-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148525000099/angn-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001601485-25-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer